RedHill Biopharma (RDHL) Other Accumulated Expenses (2018 - 2025)

RedHill Biopharma (RDHL) has 8 years of Other Accumulated Expenses data on file, last reported at $500000.0 in Q4 2025.

• On a quarterly basis, Other Accumulated Expenses changed 0.0% year-over-year to $500000.0 in Q4 2025; TTM through Dec 2025 was $500000.0, a 0.0% change from a year earlier, with the FY2025 full-year figure at $500000.0, changed 0.0% from the prior year.
• Other Accumulated Expenses for Q4 2025 stood at $500000.0, roughly flat from $500000.0 in the prior quarter.
• Over the last five years, Other Accumulated Expenses for RDHL reached as high as $750000.0 in Q1 2021 and fell as low as $500000.0 in Q4 2024.
• Historically, Other Accumulated Expenses has averaged $672000.0 across 5 years, with a median of $750000.0 in 2021.
• Across the five-year window, Other Accumulated Expenses jumped 50.0% in 2021 and slipped 28.0% in 2023, its largest moves.
• Year by year, Other Accumulated Expenses stood at $750000.0 in 2021, then changed by 0.0% to $750000.0 in 2022, then declined by 28.0% to $540000.0 in 2023, then retreated by 7.41% to $500000.0 in 2024, then changed by 0.0% to $500000.0 in 2025.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $500000.0 in Q4 2025, $500000.0 in Q2 2025, and $500000.0 in Q4 2024.